Smallcap Radiopharm notches +12% jump on pancreatic cancer imaging win
Radiopharm Theranostics (ASX:RAD) has seen the safety profile of its pancreatic cancer imaging drug RAD 301 boosted by a published study.
The Watchlist
Previous Video
Next Video
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online